Biotech News

Ironwood Presents Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

Ironwood Pharmaceuticals (IRWD)Ironwood Pharmaceuticals2026-06-25 13:46 ESTClinical readout

IRWD (IRWD) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is irwd.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2B Studies

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Microbia Appoints Halley Gilbert as Vice President, General Counsel

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Microbia Announces Name Change to Ironwood Pharmaceuticals

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood and Forest to Present Positive Data from Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood and Collaborators Present Preclinical Data Demonstrating that Cyclic GMP Alleviates Intestinal Pain

IRWDIronwood Pharmaceuticals2026-06-25 13:46 EST

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

View all latest news

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

IRWDIronwood Pharmaceuticals2026-06-26 09:55 EST

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

IRWDIronwood Pharmaceuticals2026-06-26 09:55 EST

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

IRWDIronwood Pharmaceuticals2026-06-26 09:55 EST

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2B Studies

IRWDIronwood Pharmaceuticals2026-06-26 09:55 EST

Microbia Appoints Halley Gilbert as Vice President, General Counsel

IRWDIronwood Pharmaceuticals2026-06-26 09:55 EST

Microbia Announces Name Change to Ironwood Pharmaceuticals

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States